AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06542393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood transfusion
Description: After surgery, this group will receive one unit of RBC at the moment of ICU admission.~Hb > 8 g/dl: 1 unit of RBC. HB \< 8 g/dl: 2 units of RBC.
Study NCT06032260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched panettone
Description: Volunteers consumed 100 grams of panettone enriched with fiber (JAX Plus® (Heallo srl, Milano, Italy), a soluble fiber with Arabinoxylans from wheat and barley
Study NCT06032260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Panettone standard
Description: Volunteers consumed 100 grams of panettone standard
Study NCT05864209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phthalate- and Bisphenol-free Baby Products
Description: 3-month supply. Products include wipes and diaper cream.
Study NCT05864209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cloth Diapers
Description: Subscription to cloth diaper service.
Study NCT05952648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lower respiratory tract standard culture
Description: The lower tract respiratory samples will be analyzed using convention microbiological methods (including conventional Gram stain and semiquantitative culture on both selective/differential and screening agar media)
Study NCT05952648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lower respiratory tract standard culture
Description: The lower tract respiratory samples will be analyzed using convention microbiological methods (including conventional Gram stain and semiquantitative culture on both selective/differential and screening agar media)
Study NCT05952648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample standard culture
Description: When HAP or VAP are suspected, blood samples from peripheral vein will be collected and analyzed with conventional microbiological methods
Study NCT05952648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample standard culture
Description: When HAP or VAP are suspected, blood samples from peripheral vein will be collected and analyzed with conventional microbiological methods
Study NCT05864209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Disposable Diapers
Description: 3-month supply.
Study NCT05864209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Baby Products
Description: Products include wipes and diaper cream.
Study NCT05645822 — intervention group
Intervention type: OTHER
Intervention: Screen&treat
Description: Study participants will be tested with an RDT to prove the presence of antibodies against Trypanosoma brucei gambiense. Should the RDT be positive, they will be offered the 10-day treatment with fexinidazole, and an additional blood sample will be taken for the post hoc confirmation of the disease.
Study NCT06723990 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant standard treatment for HER2+
Description: NEOADJUVANT SETTING
Study NCT06723990 — intervention group
Intervention type: DRUG
Intervention: Adjuvant standard treatment for HER2+
Description: ADJUVANT SETTING
Study NCT05472142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UP FOR IT - practice facilitation
Description: Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The practice facilitation collaborative trains and supports clinical teams to use the Model for Improvement to make breakthrough improvements in diabetes care and DSMES utilization by recognizing barriers and changing clinical systems and care practices.
Study NCT05472142 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UP FOR IT - health information technology
Description: Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The health information technology component provides the scaffolding for quality improvement efforts by automating patient identification and enabling bi-directional referral communication between providers and diabetes self-management education and services (DSMES) programs.
Study NCT05472142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UP FOR IT - health information technology
Description: Using Practice Facilitation and Operationalizing Referral Information Technology (UP FOR IT) involves incorporation of health information technology and practice facilitation. The health information technology component provides the scaffolding for quality improvement efforts by automating patient identification and enabling bi-directional referral communication between providers and diabetes self-management education and services (DSMES) programs.
Study NCT06511076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Description: Participants will receive a single sc injection of zilucoplan in the pre-specified sequence.
Study NCT06343662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MERAKI_ABI
Description: The music therapy session will focus on the themes of reidentification and involvement. The aim is to accompany the patient during the illness process, allowing them to express their emotional state, relate to music, promote listening and communication between family members, help and value preserved abilities, and promote personal involvement in the rehabilitation process.~The session will work with songs, taking into account musical preferences.
Study NCT05903092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg IV on Day 1 of every Cycle
Study NCT05903092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: 1500mg IV on Day 1 of every Cycle
Study NCT05903092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin or Cisplatin
Description: On Day 1 of Cycles 1-4 by IV:~Carboplatin: AUC 5-6 OR Cisplatin: 75-80mg/m\^2
Study NCT05903092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 80-100mg/m\^2 IV on Days 1-3 of Cycles 1-4
Study NCT06528301 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UB-VV111
Description: UB-VV111 is a gene therapy that generates CD19 CAR T cells in the body.
Study NCT06528301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: Rapamycin is an FDA-approved drug.
Study NCT05156060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Taken by mouth 3 times per day
Study NCT05156060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Administered intranasally 3 times per day
Study NCT06132087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection
Study NCT06132087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06132087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal Pancreatectomy
Description: Undergo distal pancreatectomy
Study NCT06132087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: Undergo laparoscopy
Study NCT06132087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06132087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy
Description: Undergo pancreaticoduodenectomy
Study NCT06132087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06132087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgical resection
Study NCT06132087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Pancreatectomy
Description: Undergo total pancreatectomy
Study NCT05906836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally.
Study NCT05906836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.
Study NCT05370131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avatar-Based Education Program in Hydrocephalus (ABEP-H)
Description: The avatar-based education program in hydrocephalus (ABEP-H) aimed to help parents acquire the knowledge and develop the skills necessary for the care of hydrocephalus children with VP shunts and prevent shunt infection and dysfunction.
Study NCT05782062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleaner XT
Description: Wire like device that rotates to allow for wall to wall disruption of thrombus.
Study NCT05782062 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon
Description: Use of balloon for disrupting thrombus.
Study NCT05034419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym
Description: Stimulation will be done under anesthesia for 30 minutes. Stimulation parameters include a pulse width of 200 μs, amplitude of 20 mA and a pulse frequency of 20 Hz. The Parasym devise (Parasym Health, London, UK) will be used for stimulation. The device will be connected to a clip electrode that will be attached to the external ear. In the active group, the ear clip electrode will be attached to tragus in the active stimulation group. This device has been deemed non-significant risk by the FDA. In the control group, no stimulation will be done.
Study NCT05034419 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation
Study NCT05993663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arts in health group intervention
Description: 12 sessions using the Arts in Health methodology with the aim of having a better understanding of the disease, developing healthy lifestyle habits and greater emotional intelligence. Visual thinking strategies, game based activities, mindfulness and dance will be used
Study NCT06551467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Ayurveda Program for Detox and Lifestyle
Description: The program includes personalized herbal remedies, detoxification procedures, dietary guidelines, yoga exercises, and daily routine practices.
Study NCT05571969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2X-121 and dovitinib
Description: The dose levels to be evaluated in Part 1 are:~Cohort 1 600 mg (morning dose: 200 mg + evening dose: 400 mg); Cohort 2 800 mg (morning dose: 400 mg + evening dose: 400 mg); Cohort 3 1000 mg (morning dose: 400 mg + evening dose: 600 mg);~The dose levels to be evaluated in Part 2 are:~Cohort 1 2X-121 (MTD) + 300 mg dovitinib; Cohort 2 2X-121 (MTD) + 400 mg dovitinib; Cohort 3 2X-121 (MTD) + 500 mg dovitinib;
Study NCT06574386 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessment
Description: Neurodevelopmental assessment
Study NCT05957159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detoxification Program
Description: Patients will begin inpatient or outpatient detoxification prior to completing imaging
Study NCT05957159 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PKAB
Description: 90 PET Imaging Scan using \[11C\]LY2795050 (AKA \[11C\]PKAB)
Study NCT05957159 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CFN
Description: 90 Pet Imaging Scan using \[11C\]-Carfentanil
Study NCT04914975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: The stimulation will be conducted at home or at the SPC for half an hour about 30 minutes before the usual bowel emptying time. Four adhesive electrodes are attached to the abdominal wall for the neuromuscular electrical stimulation. The abdominal muscles are stimulated in such a way that activation occurs, i.e. the muscle alternately contracts and relaxes again. The stimulation sessions will be documented with a defined protocol. In addition, the stool consistency is rated according to the Bristol Stool Form Scale.
Study NCT05650255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A Digital Twin for Exoskeleton Pilot
Description: The purpose of this project is to establish a digital twin of this driving, which will perform the driving action in parallel, and calculate in parallel in the virtual environment the torque required to provide each joint torque to maintain stable walking without falling, and this torque can be used as a monitoring basis for the auxiliary torque of each axis for the exoskeleton. When the exoskeleton's movements are out of range of a stable gait, the controller can warn and attenuate the output of auxiliary forces, and on the other hand, it has the opportunity to analyze whether the intention of driving is to switch the movement mode - such as stopping, or sitting, squatting, etc.
Study NCT06153758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danuglipron
Description: Danuglipron oral tablets
Study NCT06262100 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Carragelose
Description: Application of Carragelose containing eye drops
Study NCT04789915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Add on treatment with memantine to aripiprazole.
Study NCT04789915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo add on to aripiprazole
Study NCT05956769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr
Study NCT05956769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr
Study NCT05956769 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: thromboelastography
Description: thromboelastography (TEG6)
Study NCT05956769 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: thromboelastography
Description: thromboelastography (TEG6)
Study NCT05956769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline injection
Study NCT05463081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth.
Study NCT05463081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Taking blood from a vein for Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study) and clinical blood analysis (to include the participant in the study and evaluate procedure efficiency)
Study NCT05463081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical urine test
Description: Urine sampling for Clinical urine test (to include the participant in the study).
Study NCT05463081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal smear
Description: Vaginal smear for flora investigation (to include the participant in the study and evaluate procedure efficiency)
Study NCT05463081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pelvic ultrasound
Description: Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
Study NCT05463081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Female Sexual Function Index
Description: Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
Study NCT05463081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: International Consultation on Incontinence Questionnaire - Short Form
Description: International Consultation on Incontinence Questionnaire will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
Study NCT05026177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam
Description: Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 76 weeks at a dose of 50 mg or 100 mg.
Study NCT05138939 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Red wine A
Description: 8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
Study NCT05138939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red wine A
Description: 8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
Study NCT05026177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given b.i.d. for 76 weeks
Study NCT05681845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Participants will receive a single dose of Mim8 subcutaneously in the abdomen.
Study NCT05601362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gamified Attention Bias Modification
Description: Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT).
Study NCT05601362 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gamified Placebo Training
Description: Placebo version of Gamified Attention Bias Modification. (Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias).
Study NCT05513807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide treatment
Description: 3g Nicotinamide orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
Study NCT05513807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: 3g Placebo orally (1g immediately pre transplant, then immediately 1g post-transplant after the recovery room and 1g 24 hours later)
Study NCT05132543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High density micro-electrocorticography for neural speech prothesis
Description: ECoG electrodes are thin, high-density, flexible electrode arrays used for recording electrophysiological signals from the brain.
Study NCT06260059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Patient will be given 10 mg of Empagliflozin if randomized to the drug arm or will receive placebo drug for 1 year
Study NCT06260059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To patients randomized to the placebo group, a placebo pill will be given
Study NCT05463081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Short Form Health Survey
Description: The Short Form Health Survey will be used to collect feedback on changes in the participants' life quality (to evaluate procedure efficiency).
Study NCT05463081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal Health Index
Description: Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
Study NCT05463081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital signs determination
Description: Vital signs determination (respiration rate, blood pressure, pulse rate, body temperature).
Study NCT05101473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: The overall framework will consist of two supervised exercise sessions per week of 30-60 min duration for 12 weeks in order to be able to result in the physiological adaptions that are needed to improve the health of the individual participant.
Study NCT05463081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pH of vagina determination
Description: Potential of hydrogen (pH) of vagina will be investigated by test-lines paper (to evaluate procedure efficiency).
Study NCT05463081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical parameters determination
Description: Physical parameters determination (body weight, age, height, body mass index).
Study NCT06479317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Oral Tablet
Description: Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.